also on other fortune lists

company facts

f500 stats

Fortune 500

Courtesy of Bristol-Meyers Squibb


Bristol-Myers Squibb


The biopharmaceutical company manufactures medicines for Alzheimer’s, dementia, pyschiatric disorders, cardiovascular, diabetes, oncology, and hepatitis.

Looking for leads, investment insights, or competitive intelligence?


Giovanni Caforio

CEO Title

Chief Executive Officer & Director


Health Care



HQ Location

New York, NY

Years on Fortune 500 List




Profile provided by S&P Global.
Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$19,42717.3%
Profits ($M)$4,457.0184.8%
Assets ($M)$33,707
Total Stockholder Equity ($M)$16,177
Market Value — as of March 31, 2017 ($M)$89,591
Profit Ratios
Profit as % of Revenues22.9%
Profits as % of Assets13.2%
Profits as % of Stockholder Equity27.6%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)2.65
EPS % Change (from 2015)184.9%
EPS % Change (5 year annual rate)4.2%
EPS % Change (10 year annual rate)12.6%
Total Return
Total Return to Investors (2016)-13.0%
Total Return to Investors (5 year, annualized)14.0%
Total Return to Investors (10 year, annualized)12.7%
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Bristol-Myers Squibb

This New Drug Combination Doubles the Chance of Keeping Lung Cancer at Bay

The finding could result in annual sales of $4.6 billion by 2023.

Read More →
Supreme Court Ruling Could Save J&J Millions in Talc Cancer Lawsuits

The ruling led a St. Louis judge at J&J's urging to declare a mistrial in the latest talc case.

Read More →
The U.S. Supreme Court Has Been Incredibly Pro-Business This Term

Here are six rulings from 19 cases in which the U.S. Chamber of Commerce participated.

Read More →
3 Key Takeaways from the World's Biggest Cancer Conference

Promising cancer drugs took center stage at ASCO 2017, which wraps up Tuesday.

Read More →
Why Merck's Keytruda Just Became a Lung Cancer Game Changer

A new FDA approval gives Merck a huge advantage over its rivals.

Read More →